You are here: Home > Our Business > Pipeline



1533546751824359.jpgPCV13i is an improved pneumococcal conjugate vaccine

 being developed by us, 13-valent vaccine primarily used

 for the prevention of invasive pneumococcal diseases. 

We are also developing a potential China best-in-class 

PCV13. Currently, PPV23 products are the primary pneumococcal

 vaccines in China, in contrast with most developed countries where PCV13 products are predominantly used. Compared with Prevnar 13 and other PCV13 candidates, our PCV13i incorporates key improvements in conjugate design and manufacturing processes. As a result, our PCV13i has shown better immunogenicity than Prevnar 13 in pre-clinical studies. We plan to file the CTA for our PCV13i candidate by the end of 2018.